Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
PF-07921585 in MSS/MSI-L/pMMR cancer: NCT06580938 Clinical Landscape Report 2026
15 October 2026
NCT06580938 clinical landscape for MSS/MSI-L/pMMR cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Renal Cell Carcinoma: NCT06584435 Clinical Landscape Report 2026
15 October 2026
NCT06584435 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
QXL-138AM in Hepatocellular Carcinoma: NCT06582017 Clinical Landscape Report 2026
15 October 2026
NCT06582017 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TS-2021 in Glioblastoma Multiforme: NCT06585527 Clinical Landscape Report 2026
15 October 2026
NCT06585527 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HMPL-760 in Diffuse large B-cell lymphoma recurrent: NCT06601504 Clinical Landscape Report 2026
15 October 2026
NCT06601504 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
HUC-MSC-sEV-001 Nasal Drops(Xuanwu Hospital ) in Amyotrophic Lateral Sclerosis: NCT06598202 Clinical Landscape Report 2026
15 October 2026
NCT06598202 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NB-4746 in Neurodegenerative Diseases: ACTRN12624001072505 Clinical Landscape Report 2026
15 October 2026
ACTRN12624001072505 clinical landscape for Neurodegenerative Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
IMSA-101 in Metastatic Renal Cell Carcinoma: NCT06601296 Clinical Landscape Report 2026
15 October 2026
NCT06601296 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Utidelone in Metastatic breast cancer: NCT06598046 Clinical Landscape Report 2026
15 October 2026
NCT06598046 clinical landscape for Metastatic breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06595186 Clinical Landscape Report 2026
15 October 2026
NCT06595186 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Izalontamab Brengitecan in Recurrent Glioblastoma: NCT06598787 Clinical Landscape Report 2026
15 October 2026
NCT06598787 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Diffuse Large B-Cell Lymphoma: NCT06594640 Clinical Landscape Report 2026
15 October 2026
NCT06594640 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.